Press Release

Adaptive Biotechnologies to Present at the BofA Securities 2020 Healthcare Conference

05-06-2020

SEATTLE, May 06, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities Virtual Healthcare Conference.

Adaptive Biotechnologies’ management is scheduled to present on Wednesday, May 13th at 12:00 p.m. Pactific Time / 3:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.       

Investor Contact:
Carrie Mendivil
investors@adaptivebiotech.com 

Media Contact:
Beth Keshishian
media@adaptivebiotech.com 

FINAL Adaptive_Logo_Registered_PNG_5-11-15(1).png

Source: Adaptive Biotechnologies